BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37278135)

  • 1. Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study.
    Billiet A; Temmerman F; Coudyzer W; Van den Ende N; Colle I; Francque S; De Maeght S; Janssens F; Orlent H; Sprengers D; Delwaide J; Decock S; De Vloo C; Moreno C; van Malenstein H; van der Merwe S; Verbeek J; Nevens F
    United European Gastroenterol J; 2023 Sep; 11(7):633-641. PubMed ID: 37278135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a polycystic liver disease complaint-specific assessment (POLCA).
    Temmerman F; Dobbels F; Ho TA; Pirson Y; Vanslembrouck R; Coudyzer W; Bammens B; van Pelt J; Pirenne J; Nevens F
    J Hepatol; 2014 Nov; 61(5):1143-50. PubMed ID: 24996047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
    Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
    Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
    Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts.
    Neijenhuis MK; Wijnands TFM; Kievit W; Ronot M; Gevers TJG; Drenth JPH
    Eur Radiol; 2019 Jun; 29(6):3062-3068. PubMed ID: 30542749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
    Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
    Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.
    Neijenhuis MK; Gevers TJ; Hogan MC; Kamath PS; Wijnands TF; van den Ouweland RC; Edwards ME; Sloan JA; Kievit W; Drenth JP
    Hepatology; 2016 Jul; 64(1):151-60. PubMed ID: 26970415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
    Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
    Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
    Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
    Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug holiday in patients with polycystic liver disease treated with somatostatin analogues.
    van Aerts RMM; Kolkman M; Kievit W; Gevers TJG; Nevens F; Drenth JPH
    Therap Adv Gastroenterol; 2018; 11():1756284818804784. PubMed ID: 30302127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
    van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
    Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life.
    Duijzer R; Barten TRM; Staring CB; Drenth JPH; Gevers TJG
    J Clin Gastroenterol; 2022 Oct; 56(9):731-739. PubMed ID: 35997709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
    Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
    Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
    JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the clinical application of the polycystic liver disease questionnaire: determination of a clinical threshold to select patients for therapy.
    Barten TRM; Staring CB; Hogan MC; Gevers TJG; Drenth JPH;
    HPB (Oxford); 2023 Aug; 25(8):890-897. PubMed ID: 37095030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
    Cnossen WR; Drenth JP
    Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of liver volume on polycystic liver disease-related symptoms and quality of life.
    Neijenhuis MK; Kievit W; Verheesen SM; D'Agnolo HM; Gevers TJ; Drenth JP
    United European Gastroenterol J; 2018 Feb; 6(1):81-88. PubMed ID: 29435317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of polycystic liver disease. Update on the management.
    Aussilhou B; Dokmak S; Dondero F; Joly D; Durand F; Soubrane O; Belghiti J
    J Visc Surg; 2018 Dec; 155(6):471-481. PubMed ID: 30145049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of polycystic liver disease.
    Gevers TJ; Drenth JP
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):101-8. PubMed ID: 23296249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.